Group 1 - The company held its 16th meeting of the second board of directors, where all 13 attending directors voted in favor of the proposals presented [1][2] - The board approved the profit distribution plan for the first half of 2025, which will be submitted for shareholder meeting review [2] - The board also approved the 2025 half-year report and its summary, which had been reviewed by the audit committee prior to the board meeting [2][3] Group 2 - A special report on the management and use of raised funds for the first half of 2025 was also approved unanimously by the board [3] - The board agreed to convene the second extraordinary general meeting of shareholders in 2025, with all directors voting in favor [3]

经济观察网 2025年8月21日，信通电子(001388)发布2025年半年度报告，2025年上半年实现营业收入 4.48亿元，同比增长10.85%；实现净利润5049.63万元，同比增长5.83%；基本每股收益0.43元；加权平 均净资产收益率ROE为5.75%。 ...

经济观察网 2025年8月21日，温州宏丰(300283)发布2025年半年度报告，2025年上半年实现营业收入 16.87亿元，同比增长28.53%；实现净利润-381.3万元，同比下降45.01%；基本每股收益-0.01元；加权 平均净资产收益率ROE为-0.45%。 ...

经济观察网 2025年8月21日，征和工业(003033)发布2025年半年度报告，2025年上半年实现营业收入 9.05亿元，同比增长7.18%；实现净利润8900.17万元，同比增长49.13%；基本每股收益1.09元；加权平 均净资产收益率ROE为6.82%。 ...

Core Viewpoint - The company reported a slight increase in revenue but a significant decline in net profit for the first half of 2025 [1] Financial Performance - The company achieved operating revenue of 124 million yuan, representing a year-on-year growth of 0.44% [1] - The net profit attributable to shareholders was 19.26 million yuan, showing a year-on-year decrease of 34.87% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 14.78 million yuan, down 48.63% year-on-year [1] - Basic earnings per share were reported at 0.30 yuan [1]

Core Viewpoint - The board of directors of Beijing Tiantan Biological Products Co., Ltd. has approved several key resolutions during its 24th meeting, including the approval of the 2025 semi-annual report and profit distribution plan, as well as the establishment of a new plasma collection station project [1][2][3]. Group 1: Financial Reports and Profit Distribution - The board approved the 2025 semi-annual report and its summary with a unanimous vote of 9 in favor [1]. - The profit distribution plan for the first half of 2025 was approved, with a total distribution amount of 296,605,716.90 yuan (including tax), with no stock dividends or capital reserve transfers [1][2]. Group 2: Fund Management and Risk Assessment - The board approved the special report on the storage and actual use of raised funds for the first half of 2025, with a unanimous vote of 9 in favor [2]. - A risk assessment report regarding China National Pharmaceutical Group Financial Co., Ltd. was approved, indicating no significant deficiencies in risk management and that the financial services provided were fair and reasonable [2][3]. Group 3: Corporate Governance and New Projects - The board approved the rules for the general manager's office meetings with a unanimous vote of 9 in favor [3]. - The board agreed to the investment in the construction of a new plasma collection station by Chengdu Rongsheng Pharmaceutical Co., Ltd., with the project receiving prior approval from the strategic and investment committee [3]. - The company agreed to donate 400,000 yuan to the Gansu Red Cross for emergency disaster relief and post-disaster reconstruction efforts [3].

Group 1 - The company held its 7th meeting of the 2nd board of directors on August 10, 2025, with all 7 directors present, ensuring compliance with legal and regulatory requirements [1] - The board approved the 2025 semi-annual report and its summary, which details the company's operational performance for the first half of 2025 [1] - The board's audit committee reviewed and approved the special report on the use of raised funds as of June 30, 2025, with a unanimous vote of 7 in favor [2] Group 2 - The company plans to use up to RMB 400 million (including RMB 400 million) of temporarily idle raised funds for cash management, valid for 12 months from the board's approval [2] - The company also intends to use up to RMB 900 million (including RMB 900 million) of idle self-owned funds for cash management, also valid for 12 months from the board's approval [3]

格隆汇8月21日丨科信技术(300565.SZ)公布2025年半年度报告，上半年公司实现营业收入3.04亿元，同 比增长51.08%；归属于上市公司股东的净利润-4313.00万元；归属于上市公司股东的扣除非经常性损益 的净利润-4391.51万元；基本每股收益-0.17元。 ...

□适用 ?不适用 公司报告期控股股东未发生变更。 实际控制人报告期内变更 □适用 ?不适用 公司报告期实际控制人未发生变更。 | 翰博高新材料（合肥）股份有限公司 | | | 2025 年半年度报告摘要 | | | --- | --- | --- | --- | --- | | 证券代码：301321 | | | 证券简称：翰博高新 | | | 翰博高新材料（合肥）股份有限公司 | | | | | | 翰博高新材料（合肥）股份有限公司 | | | | 2025 年半年度报告 | | 摘要 | | | | | | 一、重要提示 | | | | | | 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 | | | | | | 资者应当到证监 | | | | | | 会指定媒体仔细阅读半年度报告全文。 | | | | | | 所有董事均已出席了审议本报告的董事会会议。 | | | | | | 非标准审计意见提示 | | | | | | □适用 ?不适用 | | | | | | 董事会审议的报告期利润分配预案或公积金转增股本预案 | | | | | | □适用 ?不适用 | ...

证券代码：605183 证券简称：确成股份 公告编号：2025-038 确成硅化学股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、 会议召开和出席情况 确成硅化学股份有限公司（以下简称"公司"）第五届董事会第三次会议于 于 2025 年 8 月 8 日以邮件方式发出。公司现有董事 7 人，出席会议并表决的董 事 7 人。 董事会认为：公司 《2025 年半年度报告及其摘要》的编制和审议程序符合 相关法律、法规及《公司章程》等内部规章制度的规定；公司 《2025 年半年度 报告及其摘要》的内容真实、准确、完整，无虚假记载、误导性陈述或者重大遗 漏，内容与格式符合相关规定，公允地反映了公司 2025 年半年度的财务状况和 经营成果等事项；公司 2025 年半年度报告及其摘要编制过程中，未发现公司参 与半年度报告编制和审议的人员有违反保密规定的行为。 本议案已经公司第五届董事会审计委员会第二次会议审议通过并同意提交 董事会审议。 详情请见同日在上海证券交易所网站（www.sse.com.cn）上的披露的《20 ...